

## Inventiva to Present at Two Upcoming Investor Conferences

**Daix (France), November 13, 2017** – 05:45pm CEST, Inventiva, a biopharmaceutical company developing innovative therapies, particularly for the treatment of fibrotic diseases, today announced that Frédéric Cren, Chief Executive Officer of Inventiva, will present at two upcoming investor conferences; the details are as follows:

### **Jefferies 2017 London Healthcare Conference**

Date: November 16, 2017  
Time: 8:00am Greenwich Mean Time  
Location: The Waldorf Hilton; London, UK

### **Piper Jaffray 29<sup>th</sup> Annual Healthcare Conference**

Date: November 28, 2017  
Time: 8:30am Eastern Standard Time  
Location: Lotte New York Palace Hotel; New York, NY

### **About Inventiva:** [www.inventivapharma.com](http://www.inventivapharma.com)

Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva's research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment with a strong action mechanism permitting the activation of all three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing in parallel, a second clinical product, Odiparcil (formerly IVA336), which is a treatment for three different forms of mucopolysaccharidosis: MPS I or Hurler/Scheie syndromes, MPS II or Hunter syndrome and MPS VI also known as Maroteaux-Lamy syndrome. Inventiva is also developing a preclinical stage oncology portfolio.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie. Two strategic R&D partnerships have also been established with AbbVie and Boehringer Ingelheim, making Inventiva eligible for preclinical, clinical, regulatory and commercial milestone payments, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

### **Contacts**

#### **Inventiva**

Frédéric Cren  
Chief Executive Officer  
[info@inventivapharma.com](mailto:info@inventivapharma.com)  
+33 (0)3 80 44 75 00

#### **NewCap**

Julien Perez /  
Mathilde Bohin  
Investor Relations  
[inventiva@newcap.eu](mailto:inventiva@newcap.eu)  
+33 (0)1 44 71 98 52

#### **NewCap**

Nicolas Merigeau /  
Arthur Rouillé  
Media Relations  
[inventiva@newcap.eu](mailto:inventiva@newcap.eu)  
+33 (0)1 44 71 94 98

#### **LifeSci Advisors**

Chris Maggos  
Investor Relations  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)  
+41 79 367 6254

**Important Notice:**

*Some of the statements contained in this document are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements.*

*Please refer to the « Document de référence » filed with the Autorité des Marchés Financiers on April 26, 2017 under n° R.17-025 for additional information in relation to such factors, risks and uncertainties.*

*Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently Inventiva accepts no liability for any consequences arising from the use of any of the above statements.*